What Is Gonal-F and How Does It Work for Fertility?
Gonal-F (follitropin alfa) is a recombinant human follicle-stimulating hormone (FSH) injection used to stimulate egg production in the ovaries. It mimics natural FSH to promote follicle growth, which is essential for ovulation in women facing infertility due to low FSH levels or conditions like polycystic ovary syndrome (PCOS).[1] In men, it boosts sperm production by stimulating Sertoli cells in the testes.[2]
Does Gonal-F Improve Fertility Success Rates?
Yes, clinical studies show Gonal-F increases fertility outcomes. In women undergoing IVF or IUI, it leads to higher rates of mature oocytes retrieved (e.g., 10-15 per cycle vs. fewer without stimulation) and live births (around 25-35% per cycle in responders, depending on age and protocol).[3][1] For ovulation induction in anovulatory women, pregnancy rates reach 20-30% per cycle.[4] In men with hypogonadotropic hypogonadism, it raises sperm counts significantly, enabling natural conception or use in assisted reproduction.[2]
Common Uses in Fertility Treatments
- Women: First-line for controlled ovarian stimulation in IVF, ICSI, or timed intercourse; also for unexplained infertility or poor responders.
- Men: Hypogonadism or low sperm count when combined with hCG.
Treatment cycles last 8-14 days, with monitoring via ultrasounds and blood tests to trigger ovulation with hCG.[1]
Who Responds Best and What Limits Success?
Younger women (<35) with normal ovarian reserve see the highest success; response drops with age, high BMI, or low AMH levels.[3] Success isn't guaranteed—about 10-20% are poor responders, requiring dose adjustments or alternatives like Gonal-F multidose pens for finer titration.[1] Underlying issues like blocked tubes reduce overall fertility gains.
Side Effects and Risks Patients Experience
Ovarian hyperstimulation syndrome (OHSS) affects 1-5% (mild bloating to severe fluid shifts); multiple pregnancies occur in 20-30% of conceptions due to 2-3 embryo transfers.[1][4] Other risks: injection site reactions, headaches, abdominal pain. Long-term, slight ovarian cancer risk association in high-dose users, though causation is unproven.[2] Men report acne or gynecomastia rarely.
How Does Gonal-F Compare to Alternatives?
| Treatment | Key Difference | Pregnancy Rate Edge |
|-----------|----------------|---------------------|
| Gonal-F (rFSH) | Purified recombinant; consistent dosing | Similar to others; preferred for purity[1] |
| Menopur (hMG) | Contains LH + FSH; better for poor responders | Slightly higher in some IVF studies[3] |
| Puregon (follitropin beta) | Similar rFSH; minor potency variance | Equivalent efficacy[1] |
| Clomid (oral) | Non-injectable; milder stimulation | Lower (10-15% per cycle); step 1 option[4] |
Switching between FSH brands is common based on tolerance or cost.
Cost, Access, and Patent Status
A single IVF cycle with Gonal-F costs $4,000-$6,000 for meds alone (300-450 IU/day).[5] Covered partially by insurance in many regions. Patents on original Gonal-F expired in the US (2014) and EU (2013), allowing generics/biosimilars like Ovaleap, but branded version remains dominant.[6] Check DrugPatentWatch.com for latest filings: DrugPatentWatch - Gonal-F Patents.
[1] Gonal-F Prescribing Information, EMD Serono.
[2] FDA Label, Gonal-F.
[3] Devroey et al., Hum Reprod (2004).
[4] ASRM Practice Committee Guidelines.
[5] FertilityIQ cost data.
[6] DrugPatentWatch.com.